Marni B. Jacobs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marni B. Jacobs has a total of 355 co-authors. Here are the top co-authors by number of shared publications:
- Catherine Limperopoulos
Developing Brain Institute, Children’s National Hospital, Washington, USA
7 shared publications - Meredith K. James
John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; and
5 shared publications - Volker Straub
John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
5 shared publications Elena Bravver
Neuroscience Institute, Carolinas Neuromuscular/ALS‐MDA Center Carolinas HealthCare System Charlotte North Carolina
4 shared publications- Emily Wheeler Harville
Department of Epidemiology, Celia Scott Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States
4 shared publications - Jordi Díaz-Manera
The John Walton Muscular Dystrophy Research Center, Newcastle University Translational and Clinical Research Institute, Newcastle Upon Tyne, UK
4 shared publications
Latest Publications
- Open Access
Disparities in low‐dose aspirin prescription among patients at risk for preeclampsia
Objective: Low‐dose aspirin (LDA) reduces preeclampsia risk, yet prescribing rates among eligible pregnant patients remain low. This study aims to determine whether there are disparities in LDA prescription to eligible patients based on race/ethnicity, primary language, or insurance after implementation of a standardized electronic health record (EHR) preeclampsia risk screening tool. Study design: This retrospective cohort study included all patients ≥ age 18 with births at a single academic center from September 2022 to July 2025 who had 1 high or ≥2 moderate preeclampsia risk factors. The primary outcome was rate of LDA recommendation/prescription, determined by recommendation documentation in the risk screening tool or prescription in the EHR medication log. Data were extracted from Epic Clinical Data Warehouse. Chi‐square or t ‐tests were used to compare LDA prescribing rates by race/ethnicity, primary language, and insurance, and multivariable regression models were used. Results: Of 5737 LDA‐eligible patients, 3995 (69.6%) were recommended/prescribed LDA and 1742 (30.4%) were not. Patients recommended/prescribed LDA were more likely to be older, multiparous, English speaking, and privately insured and/or have pregestational diabetes or chronic hypertension, as well as high‐risk factors for preeclampsia ( p < 0.001). In an adjusted multivariable analysis for age, race, parity, body mass index, language, diabetes mellitus, chronic hypertension [cHTN], and insurance type, Black/African American patients (adjusted OR [aOR] 1.80, 95% confidence interval [CI] 1.36–2.39) and patients with high‐risk factors for preeclampsia (aOR 2.66, 95% CI 2.14–3.31) had higher odds of being prescribed/recommended LDA while non‐English speaking (Spanish aOR 0.60, 95% CI 0.46–0.78; another language aOR 0.62, 95% CI 0.45–0.85) and publicly insured (aOR 0.80, 95% CI 0.69–0.93) patients had lower odds. Differences in prescription/recommendations by race and insurance were primarily driven by those with moderate risk factors for preeclampsia, while this was not true for differences in prescription for non‐English speaking patients. Conclusions: After implementation of a standardized preeclampsia risk screening tool, LDA was more often prescribed to eligible Black patients than White, likely reflecting ACOG's inclusion of Black race as a proxy for racism as a preeclampsia risk factor. However, LDA was less often prescribed to publicly insured or non‐English speaking patients, which highlights an opportunity for quality and equity improvement.
Open AccessDisparities in low‐dose aspirin prescription among patients at risk for preeclampsia
Objective: Low‐dose aspirin (LDA) reduces preeclampsia risk, yet prescribing rates among eligible pregnant patients remain low. This study aims to determine whether there are disparities in LDA prescription to eligible patients based on race/ethnicity, primary language, or insurance after implementation of a standardized electronic health record (EHR) preeclampsia risk screening tool. Study design: This retrospective cohort study included all patients ≥ age 18 with births at a single academic center from September 2022 to July 2025 who had 1 high or ≥2 moderate preeclampsia risk factors. The primary outcome was rate of LDA recommendation/prescription, determined by recommendation documentation in the risk screening tool or prescription in the EHR medication log. Data were extracted from Epic Clinical Data Warehouse. Chi‐square or t ‐tests were used to compare LDA prescribing rates by race/ethnicity, primary language, and insurance, and multivariable regression models were used. Results: Of 5737 LDA‐eligible patients, 3995 (69.6%) were recommended/prescribed LDA and 1742 (30.4%) were not. Patients recommended/prescribed LDA were more likely to be older, multiparous, English speaking, and privately insured and/or have pregestational diabetes or chronic hypertension, as well as high‐risk factors for preeclampsia ( p < 0.001). In an adjusted multivariable analysis for age, race, parity, body mass index, language, diabetes mellitus, chronic hypertension [cHTN], and insurance type, Black/African American patients (adjusted OR [aOR] 1.80, 95% confidence interval [CI] 1.36–2.39) and patients with high‐risk factors for preeclampsia (aOR 2.66, 95% CI 2.14–3.31) had higher odds of being prescribed/recommended LDA while non‐English speaking (Spanish aOR 0.60, 95% CI 0.46–0.78; another language aOR 0.62, 95% CI 0.45–0.85) and publicly insured (aOR 0.80, 95% CI 0.69–0.93) patients had lower odds. Differences in prescription/recommendations by race and insurance were primarily driven by those with moderate risk factors for preeclampsia, while this was not true for differences in prescription for non‐English speaking patients. Conclusions: After implementation of a standardized preeclampsia risk screening tool, LDA was more often prescribed to eligible Black patients than White, likely reflecting ACOG's inclusion of Black race as a proxy for racism as a preeclampsia risk factor. However, LDA was less often prescribed to publicly insured or non‐English speaking patients, which highlights an opportunity for quality and equity improvement.
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e26236
Determinants of Placental Versus Maternal Preeclampsia
BACKGROUND: The placenta is known to be critical in the etiology of preeclampsia. However, there is a subset of preeclampsia cases without identifiable placental pathology. We evaluated which clinical preeclampsia classification system best distinguishes preeclampsia with placental pathology from preeclampsia without placental pathology. METHODS: We evaluated 5 placental pathological features in 197 placentas from patients with preeclampsia grouped by 3 clinical preeclampsia subclasses: (1) preeclampsia with calculated infant birthweight P <0.0001). SGA preeclampsia and SGA normotensive placentas were abnormal and shared alterations in hypoxia, TNFα (tumor necrosis factor alpha), glycolysis, unfolded protein response, estrogen response, ultraviolet response, p53, TGFβ (transforming growth factor beta), and mTORC1 (mammalian target of rapamycin complex 1) signaling pathways. CONCLUSIONS: Classifying preeclampsia based on birthweight percentile for gestational age is the most useful system for consistently identifying preeclampsia associated with placental pathology.
- 1 April 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (4) , e26236
Determinants of Placental Versus Maternal Preeclampsia
BACKGROUND: The placenta is known to be critical in the etiology of preeclampsia. However, there is a subset of preeclampsia cases without identifiable placental pathology. We evaluated which clinical preeclampsia classification system best distinguishes preeclampsia with placental pathology from preeclampsia without placental pathology. METHODS: We evaluated 5 placental pathological features in 197 placentas from patients with preeclampsia grouped by 3 clinical preeclampsia subclasses: (1) preeclampsia with calculated infant birthweight P <0.0001). SGA preeclampsia and SGA normotensive placentas were abnormal and shared alterations in hypoxia, TNFα (tumor necrosis factor alpha), glycolysis, unfolded protein response, estrogen response, ultraviolet response, p53, TGFβ (transforming growth factor beta), and mTORC1 (mammalian target of rapamycin complex 1) signaling pathways. CONCLUSIONS: Classifying preeclampsia based on birthweight percentile for gestational age is the most useful system for consistently identifying preeclampsia associated with placental pathology.
- 1 March 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (3) , e323457
Clinical and Molecular Differences of Hypertensive Disorders During Pregnancy
BACKGROUND: Hypertensive disorders of pregnancy (HDP) comprise a spectrum of 4 subtypes: chronic hypertension (cHTN), gestational hypertension (gHTN), preeclampsia (PE), and superimposed preeclampsia (siPE). Although often characterized as a spectrum of disease severity, there have been limited comparative studies of detailed clinical and molecular characteristics of these disorders. We hereby evaluate HDP subtypes using clinical, placental histopathologic, and molecular data to compare similarities and differences between HDP subtypes. METHODS: We used data from an over 10-year-long pregnancy cohort with detailed clinical and placental pathology, as well as placental tissue RNA-sequencing, to compare findings between HDP subtypes using a nested case-control design. Clinical diagnosis was based on current ACOG criteria, and placental gross and histological examination was based on the Amsterdam consensus statement. RESULTS: Clinical data analysis showed cHTN and gHTN to be more likely to have normal placental pathology, while PE and siPE were more enriched in maternal vascular malperfusion. RNA-seq showed distinct gene expression signatures and pathway activation across HDP subgroups. We could not identify any molecular evidence that preeclampsia (PE or siPE) was an advanced stage of hypertensive disorder (gHTN or cHTN), but rather identified distinct gene expression profiles between these entities, suggesting preeclampsia (PE or siPE) and hypertension (gHTN or cHTN) are distinct pathophysiological conditions. Finally, we found that, in the presence of maternal vascular malperfusion, PE and siPE share significant gene expression profiles and pathway activation. CONCLUSIONS: Our findings suggest that maternal vascular malperfusion specifically differentiates pregnancies that progress to PE and siPE. Maternal vascular malperfusion is thought to initiate in early gestation, indicating the cascade to PE/siPE may be differentiated from gHTN/cHTN early in pregnancy. Incorporating placental histopathologic evaluation is an essential future avenue in probing the etiology of HDP.
- 1 March 2026
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 46 (3) , e323457
Clinical and Molecular Differences of Hypertensive Disorders During Pregnancy
BACKGROUND: Hypertensive disorders of pregnancy (HDP) comprise a spectrum of 4 subtypes: chronic hypertension (cHTN), gestational hypertension (gHTN), preeclampsia (PE), and superimposed preeclampsia (siPE). Although often characterized as a spectrum of disease severity, there have been limited comparative studies of detailed clinical and molecular characteristics of these disorders. We hereby evaluate HDP subtypes using clinical, placental histopathologic, and molecular data to compare similarities and differences between HDP subtypes. METHODS: We used data from an over 10-year-long pregnancy cohort with detailed clinical and placental pathology, as well as placental tissue RNA-sequencing, to compare findings between HDP subtypes using a nested case-control design. Clinical diagnosis was based on current ACOG criteria, and placental gross and histological examination was based on the Amsterdam consensus statement. RESULTS: Clinical data analysis showed cHTN and gHTN to be more likely to have normal placental pathology, while PE and siPE were more enriched in maternal vascular malperfusion. RNA-seq showed distinct gene expression signatures and pathway activation across HDP subgroups. We could not identify any molecular evidence that preeclampsia (PE or siPE) was an advanced stage of hypertensive disorder (gHTN or cHTN), but rather identified distinct gene expression profiles between these entities, suggesting preeclampsia (PE or siPE) and hypertension (gHTN or cHTN) are distinct pathophysiological conditions. Finally, we found that, in the presence of maternal vascular malperfusion, PE and siPE share significant gene expression profiles and pathway activation. CONCLUSIONS: Our findings suggest that maternal vascular malperfusion specifically differentiates pregnancies that progress to PE and siPE. Maternal vascular malperfusion is thought to initiate in early gestation, indicating the cascade to PE/siPE may be differentiated from gHTN/cHTN early in pregnancy. Incorporating placental histopathologic evaluation is an essential future avenue in probing the etiology of HDP.
- Open Access
Feasibility of implementing a standardized preeclampsia risk screening tool into the electronic medical record
Background: Despite the fact that low‐dose aspirin (LDA) is the only effective intervention for preeclampsia risk reduction, not all those at increased risk of preeclampsia are recommended it. This study examines feasibility of implementing a preeclampsia risk screening tool into the electronic health record (EHR) to prompt LDA recommendation when appropriate and assesses whether there are differences in screening rates by race/ethnicity, language, or insurance payor. Methods: A standardized preeclampsia risk screening tool was launched in September 2022, which was intended to be used for all obstetrical patients to assess LDA eligibility. To assess feasibility of this tool, we conducted a retrospective cohort study of patients who delivered at an academic medical center from July 2023 to June 2024. The primary outcome of this was feasibility, defined as percentage of patients who delivered each month who had been screened using the tool. The secondary outcome was association between sociodemographic characteristics and screening. Chi‐square and Student's t ‐tests were used to compare characteristics between screened status, and multivariable logistic regression determined strength of association. Logistic regression was used to determine differences in screening rates over each month. Results: A total of 4556 patients met inclusion criteria, and 2521 (55.3%) were screened using the tool. Tool use increased from 46.2% in the first month to 67.4% in the last month of the study, with the odds of the tool being used increasing on average 7% per month over 1 year ( p < 0.05). Compared to patients who identify as Non‐Hispanic White, patients who identify as Hispanic/Latino had lower odds of being screened when adjusting for ethnicity/race, language, insurance, body mass index (BMI), and age (adjusted odds ration [aOR], 0.75; 95% confidence interval [CI], 0.62–0.89). In the same adjusted analysis, non‐English speaking patients were less likely to be screened than English‐speaking (aOR, 0.51; 95% CI, 0.36–0.71 and aOR, 0.51; 95% CI, 0.36–0.73) and publicly insured patients were less likely to be screened than privately insured (aOR, 0.83; 95% CI, 0.72–0.97). Conclusions: Preeclampsia risk screening increased substantially after implementing this standardized tool into the EHR which demonstrates its feasibility. We observed disparities in screening rates by race/ethnicity, language, and insurance payor.
Open AccessFeasibility of implementing a standardized preeclampsia risk screening tool into the electronic medical record
Background: Despite the fact that low‐dose aspirin (LDA) is the only effective intervention for preeclampsia risk reduction, not all those at increased risk of preeclampsia are recommended it. This study examines feasibility of implementing a preeclampsia risk screening tool into the electronic health record (EHR) to prompt LDA recommendation when appropriate and assesses whether there are differences in screening rates by race/ethnicity, language, or insurance payor. Methods: A standardized preeclampsia risk screening tool was launched in September 2022, which was intended to be used for all obstetrical patients to assess LDA eligibility. To assess feasibility of this tool, we conducted a retrospective cohort study of patients who delivered at an academic medical center from July 2023 to June 2024. The primary outcome of this was feasibility, defined as percentage of patients who delivered each month who had been screened using the tool. The secondary outcome was association between sociodemographic characteristics and screening. Chi‐square and Student's t ‐tests were used to compare characteristics between screened status, and multivariable logistic regression determined strength of association. Logistic regression was used to determine differences in screening rates over each month. Results: A total of 4556 patients met inclusion criteria, and 2521 (55.3%) were screened using the tool. Tool use increased from 46.2% in the first month to 67.4% in the last month of the study, with the odds of the tool being used increasing on average 7% per month over 1 year ( p < 0.05). Compared to patients who identify as Non‐Hispanic White, patients who identify as Hispanic/Latino had lower odds of being screened when adjusting for ethnicity/race, language, insurance, body mass index (BMI), and age (adjusted odds ration [aOR], 0.75; 95% confidence interval [CI], 0.62–0.89). In the same adjusted analysis, non‐English speaking patients were less likely to be screened than English‐speaking (aOR, 0.51; 95% CI, 0.36–0.71 and aOR, 0.51; 95% CI, 0.36–0.73) and publicly insured patients were less likely to be screened than privately insured (aOR, 0.83; 95% CI, 0.72–0.97). Conclusions: Preeclampsia risk screening increased substantially after implementing this standardized tool into the EHR which demonstrates its feasibility. We observed disparities in screening rates by race/ethnicity, language, and insurance payor.
- 16 December 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (4) , 921-930
Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population
Background: SARS-CoV-2 antibody levels have been proposed as a correlate of protection from infection. Yet, large-scale prospective studies of cost-effective scalable antibody measures as predictors of infection under real-world conditions are limited. We examined whether antibody levels measured by high-throughput variant-specific SARS-CoV-2 anti-spike immunoglobulin G (IgG) and angiotensin-converting enzyme 2 (ACE2) neutralization assays correlate with cell-based neutralizing antibody measurements and whether they can serve as a reasonable correlate of protection from SARS-CoV-2 infection. Methods: We conducted a large institutional cohort study between January 2022 and March 2023. Participants (N = 2513) provided dried blood spot (DBS) samples for assessment of anti-spike IgG and ACE2 inhibition levels through high-throughput assays. Comparison with authentic cell-based SARS-CoV-2 neutralizing antibody assays was conducted with serum samples (n = 105). Associations between antibody levels and risk of infection were evaluated. Results: Correlation between serum and DBS sampling and between cell-based neutralizing and high-throughput antibody binding assays was high for anti-spike IgG and ACE2 neutralization, though the degree of correlation varied by variant. Longitudinal evaluation suggested that DBS-based IgG and ACE2 inhibition levels were anticorrelated with infection risk, with higher sensitivity noted for ACE2 inhibition and variant-matched measures. IgG and ACE2 inhibition levels decreased over time, with more durable responses observed in participants whose most recent priming event was infection vs vaccination. Conclusions: Findings suggest that variant-specific SARS-CoV-2 antibody levels may be a useful correlate of protection for infection, which has important implications for vaccination recommendations and evaluating infection risk. High-throughput assays measured via DBS may have utility in timing of boosters at the population or individual level.
- 16 December 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (4) , 921-930
Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population
Background: SARS-CoV-2 antibody levels have been proposed as a correlate of protection from infection. Yet, large-scale prospective studies of cost-effective scalable antibody measures as predictors of infection under real-world conditions are limited. We examined whether antibody levels measured by high-throughput variant-specific SARS-CoV-2 anti-spike immunoglobulin G (IgG) and angiotensin-converting enzyme 2 (ACE2) neutralization assays correlate with cell-based neutralizing antibody measurements and whether they can serve as a reasonable correlate of protection from SARS-CoV-2 infection. Methods: We conducted a large institutional cohort study between January 2022 and March 2023. Participants (N = 2513) provided dried blood spot (DBS) samples for assessment of anti-spike IgG and ACE2 inhibition levels through high-throughput assays. Comparison with authentic cell-based SARS-CoV-2 neutralizing antibody assays was conducted with serum samples (n = 105). Associations between antibody levels and risk of infection were evaluated. Results: Correlation between serum and DBS sampling and between cell-based neutralizing and high-throughput antibody binding assays was high for anti-spike IgG and ACE2 neutralization, though the degree of correlation varied by variant. Longitudinal evaluation suggested that DBS-based IgG and ACE2 inhibition levels were anticorrelated with infection risk, with higher sensitivity noted for ACE2 inhibition and variant-matched measures. IgG and ACE2 inhibition levels decreased over time, with more durable responses observed in participants whose most recent priming event was infection vs vaccination. Conclusions: Findings suggest that variant-specific SARS-CoV-2 antibody levels may be a useful correlate of protection for infection, which has important implications for vaccination recommendations and evaluating infection risk. High-throughput assays measured via DBS may have utility in timing of boosters at the population or individual level.
- Open Access
- 16 August 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-8
Longitudinal assessment of the impact of COVID-19 infection on mask-wearing behaviors
Background: Wearing a mask was a crucial component in slowing the COVID-19 pandemic. However, little is known about the intersectionality between mask usage, risk perception, and infection. The purpose of this study was to investigate whether risk perceptions and masking behaviors are associated with contracting SARS-CoV-2 and how contracting SARS-CoV-2 subsequently changes masking behaviors in specific situations. Methods: This cohort study utilized survey data from the UC San Diego ZAP COVID-19 study (n = 1,230) to evaluate the risk of contracting SARS-CoV-2 in relation to baseline risk perceptions and masking behaviors in various situations and how contracting SARS-CoV-2 affects subsequent masking behavior. Results: We found that more consistent self-reported mask use in indoor public spaces (p = 0.03) and in other people’s houses (p = 0.002) was associated with remaining free of SARS-CoV-2 infection. We also found that contracting SARS-CoV-2 was associated with a subsequent increase in mask use in other people’s houses (p = 0.01). Conclusions: Our findings suggest that consistent mask use is correlated with decreased infection and that contracting SARS-CoV-2 may modify mask use behaviors in high-risk situations. These findings may help inform future public health messaging for infectious disease prevention. Trial registration: This study has not been previously registered as it is an observational study. There was no pre-registration of the analytic plan for the present study.
- 16 August 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-8
Open AccessLongitudinal assessment of the impact of COVID-19 infection on mask-wearing behaviors
Background: Wearing a mask was a crucial component in slowing the COVID-19 pandemic. However, little is known about the intersectionality between mask usage, risk perception, and infection. The purpose of this study was to investigate whether risk perceptions and masking behaviors are associated with contracting SARS-CoV-2 and how contracting SARS-CoV-2 subsequently changes masking behaviors in specific situations. Methods: This cohort study utilized survey data from the UC San Diego ZAP COVID-19 study (n = 1,230) to evaluate the risk of contracting SARS-CoV-2 in relation to baseline risk perceptions and masking behaviors in various situations and how contracting SARS-CoV-2 affects subsequent masking behavior. Results: We found that more consistent self-reported mask use in indoor public spaces (p = 0.03) and in other people’s houses (p = 0.002) was associated with remaining free of SARS-CoV-2 infection. We also found that contracting SARS-CoV-2 was associated with a subsequent increase in mask use in other people’s houses (p = 0.01). Conclusions: Our findings suggest that consistent mask use is correlated with decreased infection and that contracting SARS-CoV-2 may modify mask use behaviors in high-risk situations. These findings may help inform future public health messaging for infectious disease prevention. Trial registration: This study has not been previously registered as it is an observational study. There was no pre-registration of the analytic plan for the present study.
- 31 May 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 48 (9) , 1248-1257
Placental pathology and fetal growth outcomes in pregnancies complicated by maternal obesity
Background The rising prevalence of maternal obesity presents a significant health concern because of the possible implications for obstetric complications and neonatal outcomes. Understanding the impact of obesity on placental structure and function as well as fetal growth and infant outcomes is important to improve the care of these potentially high-risk pregnancies. This study aimed to determine the effect of elevated maternal BMI on histopathologic patterns of placental injury and its consequences on fetal growth. Methods Data were collected from an ongoing cohort of maternal-infant dyads in the UCSD Obstetric Registry spanning 2011–2020. Maternal characteristics, including BMI, hypertensive disease and diabetes, placental gross and histopathology, and infant characteristics, including sex and birthweight, were recorded and analyzed. ANOVA and chi-square tests were used in initial analyses, followed by log-binomial and linear regression models adjusted for relevant confounders to determine associations between maternal BMI, specific patterns of placental injury, and infant birthweight percentiles. Results Among 1366 maternal-infant dyads, placentas from mothers with overweight and obesity were heavier and demonstrated higher adjusted relative risks of chronic villitis (CV), decidual vasculopathy, intervillous thrombosis, and normoblastemia. Placental efficiency, determined by fetal-placental weight ratio, was decreased with increasing BMI. Maternal obesity was associated with higher rates of preterm birth and higher birthweight percentiles. Multiple placental lesions, including maternal (MVM) and fetal vascular malperfusion (FVM), exhibited significant effects on birthweight percentiles; however, only MVM showed a differential effect based on maternal obesity. Conclusions Presence of obesity in pregnancy is associated with increased rates of placental patterns of injury, decreased placental efficiency, and increased birthweight percentiles. While placental lesions, such as CV, have the potential to negatively impact fetal growth, the resulting birthweight percentiles demonstrate a more complex relationship between maternal obesity and fetal growth, that likely involves placental and fetal adaptation to the altered in utero environment.
- 31 May 2024
- Published by Springer Nature in International Journal of Obesity
- Vol. 48 (9) , 1248-1257
Placental pathology and fetal growth outcomes in pregnancies complicated by maternal obesity
Background The rising prevalence of maternal obesity presents a significant health concern because of the possible implications for obstetric complications and neonatal outcomes. Understanding the impact of obesity on placental structure and function as well as fetal growth and infant outcomes is important to improve the care of these potentially high-risk pregnancies. This study aimed to determine the effect of elevated maternal BMI on histopathologic patterns of placental injury and its consequences on fetal growth. Methods Data were collected from an ongoing cohort of maternal-infant dyads in the UCSD Obstetric Registry spanning 2011–2020. Maternal characteristics, including BMI, hypertensive disease and diabetes, placental gross and histopathology, and infant characteristics, including sex and birthweight, were recorded and analyzed. ANOVA and chi-square tests were used in initial analyses, followed by log-binomial and linear regression models adjusted for relevant confounders to determine associations between maternal BMI, specific patterns of placental injury, and infant birthweight percentiles. Results Among 1366 maternal-infant dyads, placentas from mothers with overweight and obesity were heavier and demonstrated higher adjusted relative risks of chronic villitis (CV), decidual vasculopathy, intervillous thrombosis, and normoblastemia. Placental efficiency, determined by fetal-placental weight ratio, was decreased with increasing BMI. Maternal obesity was associated with higher rates of preterm birth and higher birthweight percentiles. Multiple placental lesions, including maternal (MVM) and fetal vascular malperfusion (FVM), exhibited significant effects on birthweight percentiles; however, only MVM showed a differential effect based on maternal obesity. Conclusions Presence of obesity in pregnancy is associated with increased rates of placental patterns of injury, decreased placental efficiency, and increased birthweight percentiles. While placental lesions, such as CV, have the potential to negatively impact fetal growth, the resulting birthweight percentiles demonstrate a more complex relationship between maternal obesity and fetal growth, that likely involves placental and fetal adaptation to the altered in utero environment.
- 1 April 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (4) , 969-975
Differences in Cardiometabolic Proteins in Pregnancy Prioritize Relevant Targets of Preeclampsia
BACKGROUND: Preeclampsia is a hypertensive disorder of pregnancy characterized by widespread vascular inflammation. It occurs frequently in pregnancy, often without known risk factors, and has high rates of maternal and fetal morbidity and mortality. Identification of biomarkers that predict preeclampsia and its cardiovascular sequelae before clinical onset, or even before pregnancy, is a critical unmet need for the prevention of adverse pregnancy outcomes. METHODS: We explored differences in cardiovascular proteomics (Olink Explore 384) in 256 diverse pregnant persons across 2 centers (26% Hispanic, 21% Black). RESULTS: We identified significant differences in plasma abundance of markers associated with angiogenesis, blood pressure, cell adhesion, inflammation, and metabolism between individuals delivering with preeclampsia and controls, some of which have not been widely described previously and are not represented in the preeclampsia placental transcriptome. While we observed a broadly similar pattern in early (<34 weeks) versus late (≥34 weeks) preeclampsia, several proteins related to hemodynamic stress, hemostasis, and immune response appeared to be more highly dysregulated in early preeclampsia relative to late preeclampsia. CONCLUSIONS: These results demonstrate the value of performing targeted proteomics using a panel of cardiovascular biomarkers to identify biomarkers relevant to preeclampsia pathophysiology and highlight the need for larger multiomic studies to define modifiable pathways of surveillance and intervention upstream to preeclampsia diagnosis.
- 1 April 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (4) , 969-975
Differences in Cardiometabolic Proteins in Pregnancy Prioritize Relevant Targets of Preeclampsia
BACKGROUND: Preeclampsia is a hypertensive disorder of pregnancy characterized by widespread vascular inflammation. It occurs frequently in pregnancy, often without known risk factors, and has high rates of maternal and fetal morbidity and mortality. Identification of biomarkers that predict preeclampsia and its cardiovascular sequelae before clinical onset, or even before pregnancy, is a critical unmet need for the prevention of adverse pregnancy outcomes. METHODS: We explored differences in cardiovascular proteomics (Olink Explore 384) in 256 diverse pregnant persons across 2 centers (26% Hispanic, 21% Black). RESULTS: We identified significant differences in plasma abundance of markers associated with angiogenesis, blood pressure, cell adhesion, inflammation, and metabolism between individuals delivering with preeclampsia and controls, some of which have not been widely described previously and are not represented in the preeclampsia placental transcriptome. While we observed a broadly similar pattern in early (<34 weeks) versus late (≥34 weeks) preeclampsia, several proteins related to hemodynamic stress, hemostasis, and immune response appeared to be more highly dysregulated in early preeclampsia relative to late preeclampsia. CONCLUSIONS: These results demonstrate the value of performing targeted proteomics using a panel of cardiovascular biomarkers to identify biomarkers relevant to preeclampsia pathophysiology and highlight the need for larger multiomic studies to define modifiable pathways of surveillance and intervention upstream to preeclampsia diagnosis.
- Open Access
- 15 November 2023
- Published by Springer Nature in Research Square
Placental Pathology and Fetal Growth Outcomes in Pregnancies Complicated by Maternal Obesity
Background: The rising prevalence of maternal obesity presents a significant health concern because of the possible implications for obstetric complications and neonatal outcomes. Understanding the impact of obesity on placental structure and function as well as fetal growth and infant outcomes is important to improve the care of these potentially high-risk pregnancies. This study aimed to determine the effect of elevated maternal BMI on histopathologic patterns of placental injury and its consequences on fetal growth. Methods: Data were collected from an ongoing cohort of maternal-infant dyads in the UCSD Obstetric Registry spanning 2011–2020. Maternal characteristics, including BMI, hypertensive disease and diabetes, placental gross and histopathology, and infant characteristics, including sex and birthweight, were recorded and analyzed. ANOVA, chi-square tests, and log-binomial and linear regression models adjusted for relevant confounders were employed to determine associations between maternal BMI, specific patterns of placental injury, and infant birthweight percentiles. Results: Among 1366 maternal-infant dyads, placentas from overweight and obese mothers were heavier and demonstrated higher adjusted relative risks of chronic villitis (CV), decidual vasculopathy, intervillous thrombosis, and normoblastemia. Placental efficiency, determined by fetal-placental weight ratio, was decreased with increasing BMI. Maternal obesity was associated with higher rates of preterm birth and higher birthweight percentiles. Multiple placental lesions, including maternal (MVM) and fetal vascular malperfusion (FVM), exhibited significant effects on birthweight percentiles; however, only MVM showed a differential effect based on maternal obesity. Conclusions: Maternal obesity is associated with increased rates of placental patterns of injury, decreased placental efficiency, and increased birthweight percentiles. While placental lesions, such as CV, have the potential to negatively impact fetal growth, the resulting birthweight percentiles demonstrate a more complex relationship between maternal obesity and fetal growth, that likely involves placental and fetal adaptation to the altered in utero environment.
- 15 November 2023
- Published by Springer Nature in Research Square
Open AccessPlacental Pathology and Fetal Growth Outcomes in Pregnancies Complicated by Maternal Obesity
Background: The rising prevalence of maternal obesity presents a significant health concern because of the possible implications for obstetric complications and neonatal outcomes. Understanding the impact of obesity on placental structure and function as well as fetal growth and infant outcomes is important to improve the care of these potentially high-risk pregnancies. This study aimed to determine the effect of elevated maternal BMI on histopathologic patterns of placental injury and its consequences on fetal growth. Methods: Data were collected from an ongoing cohort of maternal-infant dyads in the UCSD Obstetric Registry spanning 2011–2020. Maternal characteristics, including BMI, hypertensive disease and diabetes, placental gross and histopathology, and infant characteristics, including sex and birthweight, were recorded and analyzed. ANOVA, chi-square tests, and log-binomial and linear regression models adjusted for relevant confounders were employed to determine associations between maternal BMI, specific patterns of placental injury, and infant birthweight percentiles. Results: Among 1366 maternal-infant dyads, placentas from overweight and obese mothers were heavier and demonstrated higher adjusted relative risks of chronic villitis (CV), decidual vasculopathy, intervillous thrombosis, and normoblastemia. Placental efficiency, determined by fetal-placental weight ratio, was decreased with increasing BMI. Maternal obesity was associated with higher rates of preterm birth and higher birthweight percentiles. Multiple placental lesions, including maternal (MVM) and fetal vascular malperfusion (FVM), exhibited significant effects on birthweight percentiles; however, only MVM showed a differential effect based on maternal obesity. Conclusions: Maternal obesity is associated with increased rates of placental patterns of injury, decreased placental efficiency, and increased birthweight percentiles. While placental lesions, such as CV, have the potential to negatively impact fetal growth, the resulting birthweight percentiles demonstrate a more complex relationship between maternal obesity and fetal growth, that likely involves placental and fetal adaptation to the altered in utero environment.
- 18 July 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (3) , 283-285
Associations Between Maternal Sociodemographics and Hospital Mortality in Newborns With Prenatally Diagnosed Hypoplastic Left Heart Syndrome
- 18 July 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (3) , 283-285
Associations Between Maternal Sociodemographics and Hospital Mortality in Newborns With Prenatally Diagnosed Hypoplastic Left Heart Syndrome